PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. Its lead product candidates comprise PGN-EDO51, an EDO peptide which is Phase 2 clinical trial to treat duchenne muscular dystrophy (DMD) patients that are amenable to an exon 51-skipping approach; PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and PGN-EDO53, which is in preclinical trial to treat duchenne muscular dystrophy. The company was founded in 2018 and is based in Boston, Massachusetts. Show more

Location: 321 Harrison Avenue, Boston, MA, 02118, United States | Website: https://pepgen.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

337.5M

52 Wk Range

$0.88 - $9.77

Previous Close

$4.91

Open

$4.99

Volume

471,471

Day Range

$4.70 - $5.15

Enterprise Value

292.4M

Cash

74.65M

Avg Qtr Burn

-22.5M

Insider Ownership

0.13%

Institutional Own.

59.54%

Qtr Updated

06/30/25